Ingredient or product comparison
PTD-DBM versus finasteride
Finasteride blocks the enzyme 5-alpha reductase, which converts testosterone to DHT. By reducing DHT levels, it addresses the upstream hormonal trigger of androgenetic alopecia. The 2023 CXXC5 study actually demonstrated that DHT induces CXXC5 through the PGD2
This source-based comparison does not add ratings or recommend a winner.
- Finasteride blocks the enzyme 5-alpha reductase, which converts testosterone to DHT. By reducing DHT levels, it addresses the upstream hormonal trigger of androgenetic alopecia. The 2023 CXXC5 study actually demonstrated that DHT induces CXXC5 through the PGD2 pathway, meaning finasteride and PTD-DBM target the same cascade at different points.
- Finasteride works at the very top: reduce DHT, and less CXXC5 gets produced in the first place. PTD-DBM works at the bottom: even if CXXC5 is present, prevent it from suppressing Wnt signaling.
- The dual approach could theoretically provide superior protection, reducing the amount of CXXC5 produced (finasteride) while also blocking whatever CXXC5 remains (PTD-DBM).
- Finasteride carries well-documented hormonal side effects including sexual dysfunction, which some users find intolerable. PTD-DBM is non-hormonal and applied topically, avoiding systemic hormonal effects. For individuals who cannot tolerate finasteride, PTD-DBM offers an alternative approach to addressing the same underlying pathway without hormonal manipulation. The peptides versus hormone therapy comparison provides broader context for non-hormonal intervention options.